Off the wire
1st LD Writethru: South Sudan President Kiir orders ceasefire after days of fighting  • BiH marks 21st anniversary of Srebrenica massacre  • Xinhua Insight: The sea where Chinese fishermen live and die  • Helping hundreds of millions of people out of poverty crucial for global sustainable development: UN chief  • Roundup: Vietnam's Mekong Delta likely to hit agricultural targets despite H1 losses in 2016  • Tim Duncan announces retirement after 19 seasons with Spurs  • Arab League voices concern over South Sudan deadly clashes  • Eurozone business investment rate up to 22.2 pct in Q1  • Solar-powered aircraft leaves Seville for Cairo  • World heritage meeting urges better protection of heritage  
You are here:   Home

Austrian research team develops potential AIDS treatment breakthrough

Xinhua, July 12, 2016 Adjust font size:

Austrian researchers have developed a treatment that could spell a breakthrough in the treatment of AIDS, the Krone newspaper reported on Monday.

The research duo of Thomas Szekeres, a human geneticist who also serves as president of the Vienna Medical Association, and Walter Jaeger, a pharmacist, said the arduous research project spanned 15 years.

Jaeger said while it was "full of setbacks," there were also often "new hopes," and they are now satisfied with the research results and ready to make them public.

The research is based on a substance known as resveratrol, that occurs naturally in grapes as a means of defense against fungi and bacteria.

Based on this substance as well as a similar artificially developed chemical compound known as "M8," Szekeres conducted research into a substance, that Jaeger then developed, that is to inhibit the growth of HIV.

"We have meticulously proven this in human cells. And if is effective there, it can also begin healing processes in human HIV sufferers," Szekeres said according to the report.

The researchers were assisted in the project by several Canadian institutes such as the McGill University AIDS Center and the Lady Davis Institute for Medical Research affiliated with the Jewish General Hospital. Endit